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1366Abstract: Complex regional pain syndrome (CRPS) is a potentially debilitating chronic pain syndrome
with a poorly understood but likely neuroimmune/multifactorial pathophysiology associated with
axonal injury. Based on the potential contribution of proinflammatory cytokines to CRPS pathogenesis
and prior research with thalidomide, we investigated lenalidomide, a thalidomide derivative, for CRPS
treatment. We conducted a phase II, randomized, double-blind, placebo-controlled study to evaluate
the efficacy of oral lenalidomide 10 mg once daily in consenting patients with unilateral or bilateral
CRPS type 1. The study comprised 12 weeks of treatment followed by a long-term extension. The pri-
mary efficacy outcome was reduced pain in the index limb, defined as$30% improvement from base-
line using an 11-point numeric rating scale. One hundred eighty-four subjects enrolled. The primary
endpoint was not met because equal proportions of treated (16.1%) and control (16.1%) subjects
achieved the outcome; however, lenalidomide was well tolerated, with no evidence of neuropathy
ormajor adverse effects. This study is the largest controlled, blinded clinical trial in subjectswith chronic
CRPS using the Budapest research criteria. It demonstrates the feasibility of conducting high-quality
clinical trials in CRPS type 1 and provides considerations for designing future trials.
Perspective: This article reports an adequately powered, controlled clinical trial in subjects with
CRPS. Treatment and placebo were equally effective, but the study demonstrated that lenalidomide
treatment is feasible in this population. The study provides examples to consider in designing future
CRPS trials.
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omplex regional pain syndrome (CRPS) is an often
debilitating neuropathic/neuroimmune syndrome
usually triggered by injury to a limb.7,13,34,42 Its
clinical features can include pain symptoms such as
allodynia and hyperalgesia; difficulty moving, including
reduced range of motion; changes in limb color,
temperature, appearance, and sweating; edema; and
bone changes.15,17,25,38,40 CRPS affects more females
than males (relative risk 2:1–4:1) and has an average
age of onset of 37 to 60 years.3,8,33 Its pathophysiology
is likely multifactorial,13 and far more patients have
type 1, which often involves soft-tissue and small-fiber
axonal injury,24 than type 2, which requires injury to a
major nerve.15,22,24 Treatment guidelines based on
limited available data and expert opinion recommend
physical and occupational therapy, analgesic and other
medications, interventional procedures, and
psychological therapy and support.15,27 Proposed
mechanisms include peripheral afferent and efferent as
well as central neural involvement; clinical presentation
suggests a neurogenic inflammation and/or activation
of the immune system leading to an exaggerated
inflammatory process. Regardless, there is increasing
consensus that inflammation plays an important role in
CRPS type 1.
Increased levels of proinflammatory cytokines (tumor
necrosis factor-a [TNF-a], interleukin [IL]-1b, IL-2, and
IL-6) and anti-inflammatory cytokines (IL-4 and IL-10)
have been identified in plasma and cerebrospinal fluid
andwithin the affected limbs of CRPS patients compared
with nonaffected controls.1,20,26,39 Increased levels of
TNF-a and IL-6 have been identified in blister fluid from
the skin of the affected limb when compared with the
unaffected limb.16 The elevated levels of proinflamma-
tory and anti-inflammatory cytokines found in CRPS sug-
gest that immunomodulating agents might be useful
because of their anti-inflammatory effects. Few well-
controlled and adequately powered clinical treatment
studies of anti-inflammatory agents have been per-
formed, and existing study designs vary.9,14 Small pilot
studies have also suggested possible therapeutic
avenues, including a report of observable but variable
resolution of CRPS in 2 patients treated with the TNF-a
antagonist infliximab.21 Thalidomide is a relatively selec-
tive inhibitor of TNF-a production by human monocytes,
both in vitro and in vivo, and it exerts costimulatory
effects on T-cell responses, including inhibiting proin-
flammatory cytokines and stimulating anti-
inflammatory cytokines.6 Following demonstration of
near resolution of CRPS symptoms after thalidomide
treatment in a woman with CRPS for 3 years,28 thalido-
mide was studied in 42 patients with long-standing, pre-
viously treated CRPS. Objective and subjective
improvement was observed in 17% of patients, with
14%experiencing at least modest pain relief.36 However,
use of thalidomide is limited by its well-known neurotox-
icity and teratogenicity. Teratogenicity is a particular
concern in CRPS, because most patients are female.Lenalidomide is a thalidomide derivative created in a
program to enhance the anti-inflammatory and immu-
nomodulatory properties of thalidomide while reducing
its toxicity. It is approved in the United States and Europe
for treating multiple myeloma and anemia in some
patients with myelodysplastic syndromes12,30 and in
several other countries (eg, China, Japan) for treating
multiple myeloma.4,37 Lenalidomide has approximately
1,000 times more anti-inflammatory activity in vitro
than thalidomide.6 Its pharmacologic activities include
inhibiting secretion of the proinflammatory cytokines
TNF-a, IL-1b, and IL-6, and increasing secretion of the
anti-inflammatory cytokine IL-10 from stimulated mono-
cytes.6,19 Lenalidomide’s safety and effect on reported
pain in CRPS type 1 were studied in a preliminary phase
IIa, multicenter, single-arm, open-label, 40-patient pilot
study initiated in 2003.35 The good response rates ($2-
point improvement from baseline on an 11-point
numeric rating scale [NRS]) were 28.9% at week 12 and
52.0% at week 52, and patient-rated pain and sleep
scores also improved (P < .05).35 In addition, lenalido-
mide was well tolerated, with few treatment-related
serious adverse events (AEs) and no evidence of neuro-
logic toxicity. These findings provided the rationale for
the current phase IIb, multicenter, double-blind, pla-
cebo-controlled study.Methods
Subjects
The inclusion criteria were age $18 years and CRPS
type 1 (as per Budapest research criteria17) for $1 year
with unilateral or bilateral involvement of a distal hand
or foot, with or without proximal spread, plus a CRPS-
related pain intensity score of $4 in the index limb. In
cases where both limbs were affected, subjects selected
their limb to be assessed (designated as the index
limb). For subjects with single-limb involvement, that
limb was the index limb. Because lenalidomide is struc-
turally similar to thalidomide, a human teratogen, men
and women with reproductive potential had to follow
pregnancy prevention requirements, including coun-
seling about preventing pregnancy. Subjects had to
agree to use reliable forms of contraception, andwomen
had to agree to periodic pregnancy testing. Potentially
fertile women had to submit 2 negative pregnancy tests
before randomization.
Subjects were excluded for history of stroke or deep
vein thrombosis in the past 5 years (based on experi-
ence with lenalidomide in the oncology program);
peripheral neuropathy; severe, progressive, or uncon-
trolled renal, hepatic, hematologic, endocrine, pulmo-
nary, cardiac, neurologic, or cerebral disease; any
serious medical diagnoses or abnormal laboratory test
results; or psychiatric illness that could prevent
informed consent. Additional exclusions were prior
treatment with lenalidomide or allergy to thalidomide;
1368 The Journal of Pain Lenalidomide in Complex Regional Pain Syndromepregnancy or lactation; or use of concomitant medica-
tions that increase the risk of deep vein thrombosis.
Low-dose aspirin (81 mg) was required for subjects
receiving sex hormones in any form for contraception
or treatment of menopausal symptoms.Figure 1. Study design.Study Design
This multicenter, phase IIb study was conducted from
February 2005 to April 2008 at 24 study sites in theUnited
States. It included a 2-week screening phase and a
12-week double-blind treatment phase, followed by an
optional extension phase that allowed treatment to
continue as long as benefit was maintained (Fig 1). All
subjects meeting CRPS-related morning and evening
pain intensity numerical rating scale (PI-NRS) score re-
quirements averaged over the 7-day period before
randomization ($8 recorded scores, average score $4
in affected limb) were randomized 1:1 to receive lenali-
domide 10 mg orally once daily or placebo for up to
12 weeks in the treatment phase. Concomitant therapy
for CRPS pain (opioid and nonopioid analgesics, nonste-
roidal anti-inflammatory drugs, anticonvulsants, antide-
pressants, and other nondrug therapies) was permitted if
the dose/regimen had been stable for $4 weeks before
randomization and remained stable throughout the
study. No new CRPS medications or nondrug therapies
were allowed except for limited use of a rescue medica-
tion (short-acting opioid for no more than 7 days) to
treat pain flare, trauma, or invasive procedure. During
the extension phase, subjects were permitted to initiate,
reduce, increase, or withdraw from concomitant CRPS
painmedications/nondrug therapies except for initiating
experimental therapies.
Randomization codes were generated by a Celgene
statistician not involved in the study using a randomiza-
tion program in the Statistical Analysis Software system.
Randomization was performed centrally across all cen-
ters using blocked randomization with a block size of
4. Eligible patients were randomized in a 1:1 ratio to 1
of the 2 treatment groups. Sites were provided with
drug for 4 subjects at a time, and additional shipments
were sent as required. Each qualifying subject was as-
signed the next sequential number in the series of
numbers assigned to the site. Code-break envelopes
were provided in the boxes containing the drug, and
site personnel were instructed to contact the Celgene
Medical Monitor before breaking the code. The Celgene
Clinical Supplies group worked with Xeremis, which
packaged the drugs. All subjects completing the entire
12-week double-blind phase were eligible for the exten-
sion phase. Subjects first randomized to placebo were al-
lowed to cross over to lenalidomide 10 mg/d and
continue treatment in the extension phase.
The study protocol, amendments, and informed con-
sent form were approved by the institutional review
board at each site, and the studywas conducted in accor-
dance with the International Conference on Harmonisa-
tion Guidelines for Good Clinical Practice and the
Declaration of Helsinki. All subjects provided written
informed consent before initiating study procedures.Dose Selection
The lenalidomide dose for continuous dosing in
myelodysplastic syndrome starts at 10 mg/d and can be
adjusted downward for renal function. For intermittent
dosing, such as for multiple myeloma, the dose can start
at 25 mg/d for a defined portion of the chemothera-
peutic cycle. AEs in general were dose related. Prelimi-
nary data from the open-label study in CRPS showed
lenalidomide to be well tolerated with an expected AE
profile. Subjects who responded to lenalidomide
10 mg/d reported return of their CRPS if their dose was
reduced to 5 mg/d because of AEs, and most chose to
resume10mg/d to complete the study.On thebasis of the
requirement for continuous dosing as well as experience
in other patient populations, lenalidomide 10 mg/d was
selected as the study dose.
Efficacy and Safety Assessments and
Endpoints
Subjects used an electronic diary to collect daily
morning and evening efficacy assessment data,
including the PI-NRS. The PI-NRS was presented twice
per day at set consistent times (morning and evening)
as a discrete 11-box Likert scale from 0 (no pain) to
10 (worst pain imaginable) with the instructions
‘‘Please rate your pain due to CRPS right now.’’ The pri-
mary efficacy endpoint was the PI-NRS responder rate,
with response defined as completion of the treatment
phase with a $30% reduction from baseline (ie,
improvement) in the 7-day averaged morning and eve-
ning PI-NRS score for the week before the week 12
assessment as compared with the 7-day averaged
morning and evening PI-NRS scores during the baseline
period. The secondary efficacy endpoints included
change from baseline in the Short-Form McGill Pain
Questionnaire total score and sensory and affective
subscale scores, pain intensity ratings (combined morn-
ing and evening assessments) using PI-NRS in the index
limb, sleep rating (NRS), activity level rating (NRS), sub-
ject’s assessment of CRPS signs and symptoms in the in-
dex limb, allodynia NRS score, allodynia rating
between the index limb and the normal limb at the
end of week 12 (unilateral CRPS subjects only), and
concomitant use of pain medications.
Safety assessments included type, frequency, and
severity of AEs; physical examination; vital signs; and
laboratory test results. A battery of noninvasive nerve
conduction studies were included as a safety measure
to explore the possibility of lenalidomide-induced
Manning et al The Journal of Pain 1369peripheral neuropathy, and to evaluate whether the
anti-inflammatory effects of lenalidomide could
improve nerve conduction. The principal electrophysio-
logic outcome was maximal nerve conduction velocity.
Responses were recorded from sural sensory, median
sensory, peroneal motor, and median motor nerves on
2 occasions before the onset of dosing and 2 occasions
at the end of the initial 12-week dosing period.Statistical Analysis
When the responder definition of this study was
applied to the data from the pilot study,35 the response
rate was calculated to be 34%. Based on this, plus the
19% response rate in patients with postherpetic neural-
gia who received placebo in a published study,32
response rates for the current study were hypothesized
to be 15% for placebo and 35% for lenalidomide. Using
these assumptions, a sample size of 83 subjects per group
would have 80%power to detect a significant difference
in PI-NRS score between groups using a 2-sided,
continuity-corrected c2 test at the .05 significance level.
The primary analysis used the modified intent-to-treat
population (subjectswho received at least 1 dose of study
medication and had at least 1 postdose measurement).
Differences in responder rates between groups were
assessed using the Cochran-Mantel-Haenszel test. Sub-
jectswhodiscontinued the treatment phaseprematurely,
regardless of reason,were considerednonresponders. All
comparisons used 2-tailed tests at the .05 level of signifi-
cance. Summary statistics were provided for continuous
outcomemeasures. Secondary endpointswere evaluated
with an analysis of covariance model, which included
terms of treatment, center, baseline score, concomitant
CRPS medication change status, and treatment-by-
baseline score. Analysis of covariance results presented
here are for the observed cases subpopulation of the
modified intent-to-treat population with no imputation
for missing data, thus giving varying sample sizes,
because not all data were available for all subjects.Results
Among the 184 subjects randomized, 180 received $1
dose of study medication (97.8%; the safety population)
and had $1 postdose diary measurement (the modified
intent-to-treat population). The 12-week, double-blind
treatment phase was completed by 68 subjects who
received lenalidomide (78.2%) and 79 who received
placebo (84.9%; Fig 2). The primary reason for discontin-
uation during this phase was AEs. These affected 14 sub-
jects who received lenalidomide (16.1%) and 5 subjects
who received placebo (5.4%). The mean duration of
treatment in the double-blind treatment phase was
similar between groups: 10.6 weeks with lenalidomide
and 11.4 weeks with placebo. During the 12-week
double-blind treatment phase, small numbers of subjects
receiving lenalidomide (11; 12.6%) and receiving
placebo (7; 7.5%) altered their concomitant CRPS medi-
cation (including addition, discontinuation, or dosage
change).One hundred forty-two subjects entered the extension
phase (lenalidomide, n = 64; placebo, n = 78). Ninety-four
subjects discontinued—among them, 45 receiving only
lenalidomide (70.3%) and 49 receiving lenalidomide
(62.8%) after crossing over from placebo. The primary
reason for discontinuation among subjects receiving
lenalidomide was lack of therapeutic effect (29.7%).
Among placebo subjects who crossed over to lenalido-
mide, it was AEs (24.4%). The mean duration of treat-
ment in the extension phase was 43.8 weeks for
subjects receiving lenalidomide and 46.2 weeks for pla-
cebo subjects who crossed over to lenalidomide. The
cumulative durations of treatment were 41.1 weeks
and 49.9 weeks, respectively. The baseline demographics
and characteristics of subjects are summarized in Table 1.
The study was discontinued prematurely during the
extension phase because unblinding of the data from
the double-blind treatment phase revealed that the pri-
mary efficacy endpoint had not been met. At week 12,
16.1% of subjects receiving lenalidomide and 16.1%
receiving placebo were considered responders based
on changes in PI-NRS scores. Changes (morning assess-
ments, evening assessments, and combined morning
and evening assessments) from baseline to week 12 (7-
day averaged scores) did not differ between groups
(Table 2). In addition, there were no significant differ-
ences between groups in change from baseline in the
daily sleep assessment, Short-FormMcGill Pain Question-
naire, activity level rating, and allodynia NRS score at
week 12 (Table 3; no adjustment for multiplicity was
made, so P values are for reference only).
To better understand the types of subjects in the
responder and nonresponder categories, use of concom-
itant drugs (Table 4), nondrug therapies (Table 5), and
rescue medications (Table 6) was analyzed in relation to
responder status for the lenalidomide and placebo treat-
ment groups. There were no significant differences in
these outcomes between the lenalidomide and placebo
groups, with responders using only slightly fewer
concomitant treatments, but this did not determine
responder status. The vast majority of subjects either
took no rescue medication or used the described
opioid-rescue protocol. More subjects in the placebo
group (n = 15) than lenalidomide-treated subjects
(n = 3) used nonallowed rescue therapies.
Given lenalidomide’s mechanism of action, we evalu-
ated whether subjects with higher baseline scores for
potential markers of inflammation ormicrovasculopathy
(changes in skin temperature, color, or swelling) on the
subject’s assessment of CRPS symptoms (Table 7) were
more likely to respond. The placebo group had slightly
lower assessment ratings for these symptom categories
compared to the lenalidomide-treated group, but there
were no appreciable differences between responders
and nonresponders.Safety Outcomes
During the double-blind treatment phase, at least 1 AE
was reported by 81 subjects receiving lenalidomide
(93.1%) and 76 subjects receiving placebo (81.7%).
Figure 2. Subject disposition. *Defined as all subjects who took at least 1 dose of study drug.
1370 The Journal of Pain Lenalidomide in Complex Regional Pain SyndromeCumulative data for the double-blind plus open-label
treatment phases indicated that at least 1 AE was
reported by 83 subjects receiving lenalidomide (95.4%)
and 85 placebo subjects who crossed over to lenalido-
mide (91.4%). The most common AEs are summarized
in Table 8. In the double-blind phase, at least 1 serious
AE was reported by 4 subjects receiving lenalidomide
(4.6%) (ie, decreased potassium, pain, joint sprain,
angioneurotic edema) and 6 receiving placebo (6.5%)
(ie, increased blood pressure, neuropathic pain, vomit-
ing, tremor, clostridium colitis, and respiratory failure);
cumulative data indicated that $1 serious AE was
reported in 12 subjects receiving lenalidomide (13.8%).
This included, in addition to the above, joint sprain
(n = 2), foot fracture, deep vein thrombosis, positive hu-
man chorionic gonadotropin, false-positive pregnancy
test, sick sinus syndrome, pregnancy (n = 2), neuropathic
pain, spontaneous abortion, and arthritis. Sixteen pla-
cebo subjects who crossed over to lenalidomide
(17.2%) also reported accidental overdose, hip fracture,deep vein thrombosis (n = 2), bradycardia, thyroiditis, ad-
renal insufficiency, cholecystitis, gallbladder obstruction,
allergic alveolitis, hemolytic anemia, thrombotic throm-
bocytopenic purpura, upper abdominal pain, vomiting,
or endometriosis. Treatment-related AEs led to discon-
tinuation in 18 subjects receiving lenalidomide (20.7%)
and 5 receiving placebo (5.4%); cumulative data showed
that treatment-related AEs led to discontinuation in 29
subjects receiving lenalidomide (33.3%) and 29 placebo
subjects who crossed over to lenalidomide (31.2%).
Most AEs leading to discontinuation were grade 1
(mild) or 2 (moderate). AEs led to dose reduction in 11
subjects receiving lenalidomide (12.6%) and 2 receiving
placebo (2.2%) during the double-blind phase. The
most common AE leading to reduction of lenalidomide
was rash (3.4% of subjects), and the 2 AEs in the placebo
group were clostridium colitis and conjunctivitis. Few
shifts in laboratory values from baseline were noted in
the double-blind treatment phase and the extension
phase; of those that were different, few were reported
Table 1. Subject Demographic and Baseline
Characteristics
CHARACTERISTIC
LENALIDOMIDE
(N = 87)
PLACEBO
(N = 93)
TOTAL
(N = 180)
Age, y, M (SD) 43.9 (11.4) 45.1 (11.1) 44.5 (11.2)
Age distribution, n (%)
#65 y 83 (95) 89 (96) 172 (96)
>65 y 4 (5) 4 (4) 8 (4)
Sex, n (%)
Male 22 (25) 14 (15) 36 (20)
Female 65 (75) 79 (85) 144 (80)
Race/ethnicity, n (%)
White 81 (93) 86 (93) 167 (93)
Black 3 (3) 4 (4) 7 (4)
Hispanic 1 (1) 3 (3) 4 (2)
Asian/Pacific Islander 2 (2) 0 (0) 2 (1)
Baseline CRPS PI-NRS
score, M (SD)*
7.2 (1.4)
(n = 85)
7.0 (1.7)
(n = 92)
–
Daily sleep assessment
average score, M (SD)
5.4 (1.1)
(n = 85)
5.5 (1.3)
(n = 92)
–
Abbreviations: M, mean; SD, standard deviation.
*Combined morning and evening assessments, based on a 0–10 scale, with
higher ratings indicating more severe pain.
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Manning et al The Journal of Pain 1371as AEs. Likewise, no notable shifts in thyroid function or
vital sign parameters (diastolic and systolic blood pres-
sure, pulse, temperature) were reported.
The pattern and variance of the electrophysiologic
measures in the current studywere consistent with previ-
ous reports for multicenter clinical trials of pain.2 There
were no significant differences in mean changes from
baseline to study termination for the 2 sensory or the 2
motor nerve velocities. Lenalidomide, at the doses and
for the duration tested, was not associated with slowing
of velocity, reduction in amplitude, or exacerbation of
peripheral neuropathy.Ta
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This phase IIb study evaluated the efficacy and safety of
oral lenalidomide 10 mg once daily in subjects with CRPS
type 1 based on pilot data indicating that lenalidomide
had acceptable safety and some evidence of efficacy in
CRPS.35 Although the current outcomes show no differ-
ences in efficacy between lenalidomide and placebo for
the primary and secondary endpoints, subjects tolerated
daily lenalidomide for up to 2 years without significant
safety issues, demonstrating that lenalidomide can be
well tolerated in apopulationother than cancer patients.
Importantly, all AEs reversed after lenalidomide was dis-
continued, and neurophysiologic surveillance revealed
no evidence of treatment-induced peripheral neuropa-
thy, in distinction to the neuropathy associated with
thalidomide use.28
Both the pilot study and the phase IIb study helped
identify design elements to consider for future CRPS tri-
als. For efficiency purposes, we reevaluated the assess-
ment tools and general tolerability measures used in
the open-label pilot study, acknowledging that the po-
tential for false positives was high, but the small sample
ensured that fewer subjects would be exposed to the
Table 3. Summary of Selected Secondary
Efficacy Assessments
MEAN ADJUSTED CHANGE
FROM BASELINE AT WEEK 12 LENALIDOMIDE PLACEBO P VALUE*
Daily sleep assessment (n = 85) (n = 92) .35
.11 .24
SF-MPQ (n = 85) (n = 92)
Total 6.36 3.94 .09
Sensory 4.55 2.85 .12
Affective 1.77 1.15 .16
Activity level rating (NRS) (n = 85) (n = 85) .90
.17 .19
Allodynia NRS score (n = 76) (n = 87) .16
3.65 4.37
Abbreviation: SF-MPQ, Short-Form McGill Pain Questionnaire.
*No adjustment for multiplicity was made, because the P value is for reference
only; the P value is from the analysis of covariance model adjusting for center
and baseline score.
Table 5. Concomitant Nondrug Therapy
(Double-Blind Phase)
NONDRUG THERAPY
LENALIDOMIDE, N PLACEBO, N
TOTAL
(N = 87)
RESPONDERS
(N = 14)
TOTAL
(N = 93)
RESPONDERS
(N = 15)
None 72 0 82 0
TENS 3 0 2 0
Acupuncture 5 1 1
Spinal cord stimulation 1 0 3 2
Psychological treatment 2 0 0 0
Physical therapy 10 4 7 1
Chiropractic therapy 0 0 2 0
Stellate ganglia blocks 1 1 0 0
Abbreviation: TENS, transcutaneous electrical nerve stimulation.
NOTE. The total will not equal the sample size as some subjects received >1
concomitant drug therapy.
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pilot study accurately predicted safety, but not efficacy,
in the current, adequately powered, controlled study.
The lenalidomide 10-mg/d dose was well tolerated in
this study; however, some AEs were observed. GivenTable 4. Concomitant Medication Use During
the Study Treatment Phase
TREATMENT
GROUP AND
OUTCOME
STATUS
CONCOMITANT MEDICATIONS
TOTM AD MR OP LA AC NSAID BZ OTHER
Lenalidomide
Total
n 86 18 17 66 11 39 16 7 21
M 2.9 .2 .2 .8 .1 .5 .2 .1 .2
Responder
n 14 3 2 10 2 9 3 0 2
M 2.6 .2 .1 .7 .1 .6 .2 .0 .1
Nonresponder
n 72 15 15 56 9 30 13 7 19
M 3.0 .2 .2 .8 .1 .4 .2 .1 .3
Placebo
Total
n 90 18 24 69 10 43 17 7 15
M 2.7 .2 .2 .8 .1 .5 .2 .1 .2
Responder
n 15 2 5 9 2 7 4 0 2
M 2.3 .1 .3 .6 .1 .5 .3 .0 .1
Nonresponder
n 75 16 19 60 8 36 13 7 13
M 2.7 .2 .1 .8 .1 .5 .2 .1 .2
Abbreviations: TotM, total medications used, including multiple agents within a
class; AD, antidepressants, including tricyclic agents; MR, muscle relaxants and
baclofen; OP, opioids; LA, local anesthetic preparations; AC, anticonvulsants,
including gabapentin and pregabalin; NSAID, nonsteroidal anti-inflammatory
agents; BZ, benzodiazepines, including clonazepam; Other, alpha adrenergic
agents, mexiletine, and acetaminophen; M, mean.
NOTE. The n value reflects the incidence of a particular category of medication
used during the treatment phase. If >1 medication from a category was used by
a subject, each unique medication was counted separately. The average inci-
dence of medication use is the total incidence divided by the total subjects in
that group. Four subjects (3 receiving placebo and 1 receiving lenalidomide)
do not have concomitant medication data.the lack of clear efficacy and the dose dependency of
AEs with moderate to long-term administration of lena-
lidomide, higher doses approaching 25 mg are not
advised. The quantitative sensory testing and measure-
ments of limb volume used in the pilot study, initially
thought important to include, proved difficult to
execute and were inconsistently applied in the pilot,
and thus they were not employed in this study, which
focused on pain endpoints. Streamlining the battery of
assessments was judged to be critical for larger studies.
In future studies of CRPS, the need for objective assess-
ments in pain clinical researchmust be balanced by feasi-
bility considerations.17
The current study is the largest controlled study of
people with CRPS and one of the first to employ the
Budapest research criteria for defining CRPS. These pro-
vide a useful tool for carefully selecting subjects, but
this symptom-based definition does not address poten-
tial heterogeneity in etiology or disease mechanisms,
which may have affected study results. This study wasTable 6. Rescue Medication Use (Double-Blind
Phase)
RESCUE MEDICATION
LENALIDOMIDE, N PLACEBO, N
TOTAL
(N = 87)
RESPONDERS
(N = 14)
TOTAL
(N = 93)
RESPONDERS
(N = 15)
None 72 8 61 10
Opioids 12 4 17 4
Acetaminophen 2 0 1 0
NSAID 3 0 5 0
Steroids 1 1 2 1
Muscle relaxants 2 1 4 0
Clonazepam 1 0 0 0
Lidoderm patch 1 0 0 0
Antiepileptic drug 0 0 3 0
Other 0 0 1* 0
Abbreviation: NSAID, nonsteroidal anti-inflammatory drug.
NOTE. The total will not equal the sample size, as some subjects received >1
concomitant drug therapy.
*Isometheptenemucate, dichloralphenazone, and acetaminophen combination
for migraine.
Table 7. Subject Assessment of CRPS Signs and Symptoms at Baseline Sorted by Treatment Phase
Responders and Nonresponders
CRPS SIGNS
AND SYMPTOMS
TOTAL DATA NONRESPONDERS RESPONDERS
LENALIDOMIDE
(N = 67)
PLACEBO
(N = 83)
LENALIDOMIDE
(N = 57)
PLACEBO
(N = 69)
LENALIDOMIDE
(N = 10)
PLACEBO
(N = 14)
Skin sensitivity
M 2.4 2.4 2.5 2.5 2.3 1.9
SD .8 .7 .8 .7 .8 .6
Deep joint pain
M 2.3 2.3 2.3 2.3 2.2 1.9
SD .8 .9 .8 .8 1.0 1.1
Temperature
M 2.1 2.0 2.1 2.0 2.1 2.0
SD .8 .8 .9 .8 .6 .8
Color
M 2.0 1.7 2.0 1.7 2.0 1.7
SD .8 .9 .8 .9 .8 1.0
Swelling
M 1.9 1.7 1.9 1.7 1.9 1.7
SD .9 .9 .9 1.0 .8 .8
Sweating
M 1.4 1.3 1.4 1.4 1.2 .8
SD 1.1 1.1 1.1 1.1 1.1 .9
Range of motion
M 2.2 2.2 2.2 2.2 2.5 2.1
SD .9 .9 .9 .9 .8 1.0
Start movement
M 2.1 2.0 2.1 2.1 2.3 1.5
SD .8 1.0 .9 .9 .6 1.1
Tremor
M 1.4 1.5 1.4 1.6 1.4 1.2
SD 1.0 1.0 1.0 1.0 1.0 1.2
Cramp/spasms
M 1.8 1.8 1.9 1.9 1.4 1.2
SD 1.0 1.0 1.0 .9 .8 1.1
Skin, hair, and nail symptoms
M 1.6 1.3 1.5 1.4 1.6 1.0
SD 1.1 1.0 1.1 1.0 1.1 .9
Skin ulcer/sores
M .4 .8 .4 .9 .0 .4
SD .9 1.3 1.0 1.4 .0 .9
Abbreviations: M, mean; SD, standard deviation.
NOTE. In the assessment of CRPS symptoms, subjects were presented with 12 questions based on the Budapest Criteria for the Diagnosis of CRPS.17 Only subjects with
unilateral limb involvement of CRPS completed the assessment. Each question asked the subjects to compare or rate the difference between the index (of CRPS
affected) limb and the normal (nonaffected) side ‘‘over the past week including today.’’ The responses are given as 1 to 4, with 1 being no difference, 2 minimal dif-
ference, 3 moderate difference, and 4 extreme or great difference compared with normal. The only exception to this pattern was question 12 regarding skin ulcers or
sores. In this question, subjects were asked to assess their skin on a 5-point graded scale, with 1 being no ulcers or sores, 2 healed ulcers or sores, 3 healing ulcers or
sores, 4 nonhealing or open ulcers or sores, and 5 new ulcers or sores since last visit. Data presented are for subjects who completed the baseline subject’s assessment of
CRPS signs and symptoms; the scale is expressed as mean score and standard deviation. In the lenalidomide group, 20 subjects did not have baseline values for CRPS
signs and symptoms (including 4 responders). In the placebo group, 10 subjects did not have baseline values for CRPS signs and symptoms (including 1 responder).
Manning et al The Journal of Pain 1373initiated in 2005, when only limited early cytokine
research (particularly for TNF-a) was available. In the
future, selecting subjects based on biomarker analysis
or similar mechanisms may allow potential therapies to
be better targeted to subsets of potentially responsive
subjects, as is becoming routine in cancer treatment. In
this study of a population not enriched for any specific
characteristics of CRPS subtypes, the degree of inflamma-
tory symptoms did not predict responder status. Cluster
analysis has revealed distinct CRPS populations, identi-
fying a subgroup with significant increases in plasma
cytokines, chemokines, and their soluble receptors.1This subgroupmight be a better target for trials of immu-
nomodulatory agents. In addition to altered plasma
cytokine levels, other significant changes reported in
people with CRPS include altered levels of plasma amino
acids,41 serum and saliva antioxidative parameters,11
blood levels of inflammatory monocytes,31 and altered
intestinal microbial communities.29 These markers might
help define subgroups amenable to specific treatments.
Duration of CRPS is another consideration for trial
design. Persistent CRPS is often complicated by structural
changes (eg, contractures, bone resorption) that can be
painful due to independent mechanisms that would
Table 8. Adverse Events Reported in $10% of Subjects
ADVERSE EVENT
DOUBLE-BLIND PHASE CUMULATIVE ADVERSE EVENTS
LENALIDOMIDE (N = 87) PLACEBO (N = 93) LENALIDOMIDE (N = 87) PLACEBO-TO-LENALIDOMIDE (N = 93) TOTAL (N = 180)
Rash (NOS) 27 (31) 9 (10) 32 (37) 34 (37) 66 (37)
Diarrhea 11 (13) 11 (12) 23 (26) 26 (28) 49 (27)
Nausea 14 (16) 18 (19) 19 (22) 24 (26) 43 (24)
Fatigue 10 (12) 12 (13) 14 (16) 21 (23) 35 (19)
Insomnia 7 (8) 5 (5) 12 (14) 13 (14) 25 (14)
Dizziness 9 (10) 6 (7) 13 (15) 10 (11) 23 (13)
Pruritus 10 (12) 4 (4) 13 (15) 11 (12) 24 (13)
Sinusitis (NOS) 5 (6) 3 (3) 12 (14) 16 (17) 28 (16)
Constipation 9 (10) 6 (7) 11 (13) 16 (17) 27 (15)
Headache 9 (10) 14 (15) 11 (13) 24 (26) 35 (19)
Nasopharyngitis 7 (8) 5 (5) 11 (13) 14 (15) 25 (14)
Pyrexia 6 (7) 4 (4) 11 (13) 8 (9) 19 (11)
Pharyngitis 6 (7) 4 (4) 10 (12) 7 (8) 17 (9)
Vomiting (NOS) 5 (6) 5 (5) 9 (10) 10 (11) 19 (11)
URI (NOS) 1 (1) 3 (3) 9 (10) 10 (11) 19 (11)
Muscle cramp 5 (6) 6 (7) 7 (8) 9 (10) 16 (9)
UTI (NOS) 5 (6) 7 (8) 6 (7) 17 (18) 23 (13)
Fall 3 (3) 6 (7) 6 (7) 13 (14) 19 (11)
Contusion 4 (5) 6 (7) 6 (7) 8 (9) 14 (8)
Abbreviations: NOS, not otherwise specified; URI, upper respiratory infection; UTI, urinary tract infection.
NOTE. Values are n (%).
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inflammatory contribution to CRPS pain may be more
important early, with neuropathic and structural causes
of pain dominating later.16,20,21 For instance, the
changed cytokine profiles in CRPS type 1–affected
limbs reportedly resolve within the first 6 months after
onset.23 In addition, chronic pain is associated with
changes in central mechanisms that can sustain it. In a
mouse model of arthritis, early pain responded to anti-
inflammatory agents such as ketorolac and etanercept,
but later, only gabapentin produced analgesia.5 What
appears early to be an inflammatory disease, if pro-
longed, may evolve into a more neuropathic condition.
The chronic, variable duration of CRPS in the current
study ($1 year) likely contributed to a mechanistically
heterogeneous sample in which subjects may have
comorbid conditions related to immobility and contrac-
tures also contributing to pain. We recommend that
future studies of CRPS treatments consider disease dura-
tion. Of note, early CRPS has a high rate of spontaneous
resolution that complicates assessment of treatment
benefits.
Future studies might also consider subjects’ use of
concomitant medications. This study enrolled many sub-
jects with significant pain despite polypharmacy. On
average, the subjects enrolled took >2 and as many as
10 concomitant medications, with no relationship to
response status. Perhaps they represent the intractable
subset, andno further pharmacotherapywouldbeeffica-
cious. Enrolling treatment-na€ıve patients or patientswho
have used just a few medications should be considered.
Study design details also influence outcomes. For
example, randomized withdrawal paradigms are gain-
ing popularity in analgesic trials. Here, subjects are
treated with active medication until optimal benefit isattained, and then they are randomly assigned to
continue using active medication or placebo. This can
help enrollment because every subject receives active
medication at the beginning, and return of pain may
not be as susceptible to placebo response as the onset
of pain relief.18 Randomized withdrawal design studies;
studies incorporating single-blind or double-blind, vari-
able-duration, placebo run-in phases; or other methods
might better distinguish between treatment and pla-
cebo responses. Databases of clinical trials for other
neuropathic pain indications could be examined to iden-
tify study design factors that can influence study out-
comes.10
In summary, because the current study found no ev-
idence of efficacy of lenalidomide in the sample stud-
ied, despite its relative safety, it cannot be endorsed
for the broad population of people with CRPS. Given
that failure rates are high in parallel-group, placebo-
controlled trials of pain therapies, it may be reason-
able to consider additional study of lenalidomide in
specific subgroups of patients. Factors to consider in
designing future CRPS trials include better character-
ization of potential subjects, stratification by disease
duration, use of concomitant medications, and selec-
tion of outcome measures. The findings demonstrate
the feasibility of conducting large, controlled studies
in CRPS patients. Our hope is that elements of this
study design will enhance and advance the search for
other therapies to treat CRPS.Acknowledgments
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